BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Centessa Pharmaceuticals plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:20 pm Sale | 2024-09-30 | 13G | Centessa Pharmaceuticals plc CNTA | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -8,774,570 (Position Closed) | Filing |
| 2024-02-14 10:13 am Purchase | 2023-12-31 | 13G | Centessa Pharmaceuticals plc CNTA | BIOTECHNOLOGY VALUE FUND L P | 8,774,570 9.000% | 1,880,225 (+27.27%) | Filing |
| 2022-06-16 5:24 pm Purchase | 2022-06-06 | 13G | Centessa Pharmaceuticals plc CNTA | BIOTECHNOLOGY VALUE FUND L P | 6,894,345 7.300% | 6,894,345 (New Position) | Filing |